BG Medicine is pioneering the application of Systems Biology to drug development. Its proprietary platform enables novel paths to new medicines through molecular fingerprinting of genes, proteins, and metabolites combined with powerful bioinformatics integration. Through several preclinical and human clinical trials, BGM’s platform has demonstrated unprecedented molecular characterization of disease states and drug response. BG Medicine applies its novel approach both to internal programs in Metabolic and CNS diseases, and through collaborations with leading pharmaceutical companies including AstraZeneca, élan, GlaxoSmithKline and Novartis. Flagship Managing Partner Noubar Afeyan is Executive Chairman, and Stelios Papadopoulos, Vice Chairman of SG Cowen Securities, is a Director.

www.bg-medicine.com